Pathogen specific neutralizing camelid antibodies (VHH/CaMab)are combined with potent antimicrobial peptides by a cleavable linker to create AbTids®. Attachment of the antimicrobial peptide to the larger antibody reduces its toxicity considerably and ensures the site-specific mode of action. The toxic peptide on release from the AbTids® rapidly lyses and neutralizes the pathogen. As these molecules act by physically lysing the pathogen, chances of resistance are reduced considerably. They are highly pathogen specific and is patient microbiome safe ensuring less morbidity. The modularity of the platform allows the creation of new AbTids® by rapid shuffling of the antibodies and peptides depending on the specific challenge.